Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Leading brokers name 3 ASX shares to sell today
Best Shares
4 growth shares I'd buy in June
Share Market News
Top brokers name 3 ASX shares to sell today
Mergers & Acquisitions
2 lasting impacts from the latest multi-billion ASX takeover
Share Market News
"The die is cast" RBA flags June rate cut & signals shares could be cheap
Growth Shares
Where to invest $5,000 in ASX shares this month
⏸️ Investing
The bullish case for CSL Limited (ASX: CSL)
Growth Shares
Why I would buy Cochlear and these ASX healthcare shares
Healthcare Shares
Why UBS just upgraded the ResMed share price
Growth Shares
Where to invest $5,000 in ASX 200 shares
Share Gainers
Trading update: Why the ResMed share price is soaring today
⏸️ ASX Shares
Are these the best blue chip ASX shares to buy this month?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
